Skip to content

Rational pharmacological intervention in the treatment of non-alcoholic fatty liver disease with probiotic preparations

Rational pharmacological intervention in the treatment of non-alcoholic fatty liver disease with probiotic preparations

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093180
Enrollment
Unknown
Registered
2024-11-29
Start date
2020-04-13
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease

Interventions

control group:Bicyclol Tablets,po, 50 mg/each dose, 3 times/day
intervention group:Bicyclol Tablets,po, 50 mg/each dose, 3 times/day + Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules ,po, 500 mg/each dose, 3 times/day

Sponsors

Taizhou People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years old, gender is not limited (including 18 years old and 80 years old) (2) Diagnostic criteria are based on the 2010 Guidelines for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. (3) Subjects have no history of alcohol abuse or the equivalent amount of ethanol is less than 140g per week; (4) Subjects' clinical information is complete; (5) Subjects were informed and agreed to the content of this study.

Exclusion criteria

Exclusion criteria: (1) The subject has alcoholic fatty liver or viral fatty liver; (2) Subjects with hepatocellular carcinoma or in the compensated stage of cirrhosis; (3) The subject has primary diseases of the liver, kidney, lung and endocrine; (4) The subject is pregnant or breastfeeding; (5) The subject has been treated with medications that affect gastrointestinal motility, such as fructose, microecological agents, and antibiotics, in the 4 weeks prior to enrolment; (6) The subject has poor medication compliance and is unable to take medication on time as prescribed by the physician; (7) Subjects with mental disorders or communication disorders.

Design outcomes

Primary

MeasureTime frame
Alanine aminotransferase;Aspartate Aminotransferase ;

Secondary

MeasureTime frame
total cholesterol;triglyceride; ?-Glutamyl Transferase ;blood glucose;urea nitrogen;creatinine; Colour Doppler Ultrasound of the liver;body mass index (BMI);waist circumference;IL-1ß;IL-18;lipopolysaccharide (LPS);IL-6;

Countries

China

Contacts

Public ContactHuilian Hua

Taizhou People’s Hospital

472304936@qq.com+86 159 5115 7447

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026